12-Jun-2026
Abbott Laboratories declares $0.63 dividend
Seeking Alpha News (Fri, 12-Jun 4:03 PM ET)
Abbott declares 410th consecutive quarterly dividend
PRNewswire (Fri, 12-Jun 2:30 PM ET)
TipRanks (Thu, 11-Jun 7:21 AM ET)
TipRanks (Tue, 9-Jun 8:11 PM ET)
Citrini sees new upside in healthcare stocks, updates basket
Seeking Alpha News (Tue, 9-Jun 11:41 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
TipRanks (Tue, 9-Jun 5:15 AM ET)
PRNewswire (Mon, 8-Jun 9:00 AM ET)
TipRanks (Mon, 8-Jun 4:56 AM ET)
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
PRNewswire (Sat, 6-Jun 9:00 AM ET)
PRNewswire (Wed, 27-May 9:00 AM ET)
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Abbott Laboratories trades on the NYSE stock market under the symbol ABT.
As of June 12, 2026, ABT stock price declined to $88.18 with 12,584,375 million shares trading.
ABT has a beta of -0.01, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.00 to the broad based SPY ETF.
ABT has a market cap of $153.59 billion. This is considered a Large Cap stock.
Last quarter Abbott Laboratories reported $11 billion in Revenue and $1.15 earnings per share. This beat revenue expectation by $157 million and exceeded earnings estimates by $.01.
In the last 3 years, ABT traded as high as $141.23 and as low as $81.97.
The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, SCHD, IVV, SPY.
ABT has underperformed the market in the last year with a return of -33.0%, while the SPY ETF gained +24.6%. In the last 3 month period, ABT fell short of the market, returning -19.4%, while SPY returned +9.9%. However, in the most recent 2 weeks ABT has outperformed the stock market by returning +2.2%, while SPY returned -1.7%.
ABT support price is $88.30 and resistance is $91.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.